Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: Possible mecahnisms of action

Elias Jabbour, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase). Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. FTIs have been developed and tested across a wide range of human cancers. At least 3 agents within this family have been investigated in hematologic malignancies. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar ™), both of which are orally administered, and BMS-214662, which is given intravenously. Preliminary results from clinical trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy. Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders.

Original languageEnglish (US)
Pages (from-to)2187-2195
Number of pages9
JournalLeukemia and Lymphoma
Volume45
Issue number11
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

tipifarnib
Hematologic Neoplasms
Transferases
Prenylation
Neoplasms
Proteins
Clinical Trials
Enzymes
lonafarnib

Keywords

  • Farnesyl transferase inhibitors
  • Leukemia
  • Ras pathway
  • Signal transduction

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies : Possible mecahnisms of action. / Jabbour, Elias; Kantarjian, Hagop; Cortes, Jorge.

In: Leukemia and Lymphoma, Vol. 45, No. 11, 01.11.2004, p. 2187-2195.

Research output: Contribution to journalReview article

@article{3dc76b8fe5e54071b8b2998bc90d8326,
title = "Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: Possible mecahnisms of action",
abstract = "Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase). Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. FTIs have been developed and tested across a wide range of human cancers. At least 3 agents within this family have been investigated in hematologic malignancies. These are tipifarnib (R115777, Zarnestra{\circledR}), lonafarnib (SCH66336, Sarasar ™), both of which are orally administered, and BMS-214662, which is given intravenously. Preliminary results from clinical trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy. Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders.",
keywords = "Farnesyl transferase inhibitors, Leukemia, Ras pathway, Signal transduction",
author = "Elias Jabbour and Hagop Kantarjian and Jorge Cortes",
year = "2004",
month = "11",
day = "1",
doi = "10.1080/10428190412331272677",
language = "English (US)",
volume = "45",
pages = "2187--2195",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Clinical activity of farnesyl transferase inhibitors in hematologic malignancies

T2 - Possible mecahnisms of action

AU - Jabbour, Elias

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase). Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. FTIs have been developed and tested across a wide range of human cancers. At least 3 agents within this family have been investigated in hematologic malignancies. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar ™), both of which are orally administered, and BMS-214662, which is given intravenously. Preliminary results from clinical trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy. Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders.

AB - Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase). Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. FTIs have been developed and tested across a wide range of human cancers. At least 3 agents within this family have been investigated in hematologic malignancies. These are tipifarnib (R115777, Zarnestra®), lonafarnib (SCH66336, Sarasar ™), both of which are orally administered, and BMS-214662, which is given intravenously. Preliminary results from clinical trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy. Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders.

KW - Farnesyl transferase inhibitors

KW - Leukemia

KW - Ras pathway

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=8644219632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644219632&partnerID=8YFLogxK

U2 - 10.1080/10428190412331272677

DO - 10.1080/10428190412331272677

M3 - Review article

C2 - 15512806

AN - SCOPUS:8644219632

VL - 45

SP - 2187

EP - 2195

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -